Funding for bladder cancer (BC) research has fallen behind that provided for other malignancies. This is especially the case for junior individuals. Therefore our SPORE In BC has provided one of the unique resources for seed funding available to promising young laboratory and clinical scientists with a special interest in pursuing independent translational research in BC. The overall goal of the Career Development Program (CDP) is to support and mentor when appropriate the scientific careers of these individuals to expand the number of such talented young investigators. Funding for bladder cancer focused research has lagged behind support provided for other malignancies.
The specific aims of the CDP within this Bladder Cancer SPORE renewal builds on the strengths of our current SPORE which included. Recruiting innovative entry-level and junior scientists into The University of Texas MD Anderson Cancer Center Bladder Cancer SPORE to enhance its overall translational BC research capability. Providing the opportunity for individuals with previous experience in the research and treatment of cancer at other disease sites who wish to develop expertise in BC. Promote the careers of the selected scientists by facilitating the development of skills necessary to be productive independent investigators in BC translational research. Train clinical oncologists and basic scientists who can rapidly translate basic observations in cellular and molecular biology into clinically applicable BC research programs and the design of protocols.
BC ranks 4th in terms of incidence and 1st in terms of clinical management cost among human malignancies. The training of young investigators with an interest in both basic and translational BC research are vital to provide future scientists who can impact the overall out come of this disease.
|Choi, Woonyoung; Porten, Sima; Kim, Seungchan et al. (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152-65|
|Hoang, Anthony N; Agarwal, Piyush K; Walton-Diaz, Annerleim et al. (2014) Clinical significance of ureteric 'skip lesions' at the time of radical cystectomy: the M.D. Anderson experience and literature review. BJU Int 113:E28-33|
|Benedict, W F; Fisher, M; Zhang, X-Q et al. (2014) Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFN?/Syn3 treatment in a phase l study. Cancer Gene Ther 21:91-4|
|Figueroa, Jonine D; Ye, Yuanqing; Siddiq, Afshan et al. (2014) Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet 23:1387-98|
|Culp, Stephen H; Dickstein, Rian J; Grossman, H Barton et al. (2014) Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol 191:40-7|
|Chakravarti, Deepavali; Su, Xiaohua; Cho, Min Soon et al. (2014) Induced multipotency in adult keratinocytes through down-regulation of ?Np63 or DGCR8. Proc Natl Acad Sci U S A 111:E572-81|
|Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315-22|
|Dinney, Colin P N; Hansel, Donna; McConkey, David et al. (2014) Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. Urol Oncol 32:1108-15|
|Yan, Chao; Liu, Degang; Li, Liwei et al. (2014) Discovery and characterization of small molecules that target the GTPase Ral. Nature 515:443-7|
|Lee, Eugene K; Ye, Yuanquing; Kamat, Ashish M et al. (2013) Genetic variations in regulator of G-protein signaling (RGS) confer risk of bladder cancer. Cancer 119:1643-51|
Showing the most recent 10 out of 178 publications